ClinicalTrials.gg
TerminatedNCT03387046INCREASEUpdated Feb 10, 2020Results posted

A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

A Phase 2 interventional study of D-aspartate and Placebo in Multiple Sclerosis, Relapsing-Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 17 sites in Italy. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-02-10.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated early due to slow recruitment rate.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Merck KGaA, Darmstadt, Germany.

Enrollment
18th of 21
7 · median 200
Started
2018
the only one that year
Phase 2
6 of 40
none open now
Registered
37th of 40
by date

Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, this one is the 18th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 2, and was the 37th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany as a file.
02

Study summary

The purpose of this study was to evaluate the improvement in spontaneous recovery from clinical deficits at the time of an acute relapse in RR-MS participants already receiving interferon (IFN) beta 1a with D-aspartate (versus placebo) as add-on therapy.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Relapsing remitting multiple sclerosis
  • D-Aspartate
  • interferon beta-1a
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with RR-MS, according to the revised McDonald Criteria (2010)
  • Participants with an expanded disability status scale (EDSS) score between 0 and 3 before screening visit and before relapse
  • Participants receiving treatment with IFN beta 1a 44 mcg three times a week for at least 6 months but for no more than 10 years before the screening visit
  • Female participants must be neither pregnant nor breastfeeding and must lack
  • Participants willing and able to comply with the protocol for the total duration of the study
  • Participants able to understand the purposes and the risks of the study
  • Participants have signed the appropriate written form, approved by the Independent Ethics Committee (IEC), prior to the performance of any study activities
  • For MS participants with relapse:
  • Deterioration of at least one step in a relevant Functional Systems Scale (FSS) or an increase in EDSS of 1 point or more compatible, according to physician's judgment, with the therapy prosecution
  • Relapse started within maximum 5 days before the inclusion in the study
  • MS participants without relapse with clinically stable RR-MS

Exclusion criteria

Exclusion Criteria:

  • Participants with diagnosis of primary progressive MS (PP-MS)
  • Participants have any disease other than MS that could better explain his/her signs and symptoms
  • Participants with any comorbidity with diseases that might alter synaptic plasticity (example Parkinson Disease, Alzheimer Disease, Stroke)
  • Participants receiving concomitant treatment with drugs that may alter synaptic plasticity (example, cannabinoids)
  • Participants with history or presence of any unstable medical condition (tumor or chronic infection or severe life threatening infection within the last 6 months)
  • Participants who have received any therapy within 3 months prior to the screening
  • Participants with any concomitant disease that may require chronic treatment with systemic corticosteroids or agents during the course of the study
  • Participants who have received any immunosuppressive agents other to corticosteroids, as monotherapy or combination therapy within 3 months prior to the screening visit
  • Participants with history or currently active primary or secondary immunodeficiency
  • Participants with inadequate liver function, defined by (ALT) > 3 * (ULN), or alkaline phosphatase (AP) > 2 * ULN, or total > 2 * ULN if associated with any elevation of ALT or AP
  • Participants with inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 * lower limit of normal (LLN)
  • Participants with moderate to severe renal impairment
  • Participants unable to complete an magnetic resonance imaging (MRI) ( for MRI include but are not restricted to weight >=140 kilogram (kg), pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc)
  • Participants with contraindication to gadolinium (Gd) can be enrolled into the study but cannot receive Gd contrast dyes during their MRI scans
  • Participants receiving supplements that, in the Investigator's opinion, may affect the evaluation of fatigue
  • Participants with any known contraindications or to D-aspartate or any
  • Participants with any other significant disease that in the Investigator's opinion would impede study assessments or endanger the participant
  • Female participants with positive pregnancy test at baseline or participants with active project of pregnancy during the study
  • Participants with legal incapacity or limited legal capacity
  • Participants have participated in any other study within 8 weeks before the screening visit
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    D-aspartate + IFN beta-1a + Methylprednisolone

    Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.

    Dietary Supplement: D-aspartate · Biological: IFN beta-1a · Drug: Methylprednisolone

  • Placebo comparator
    Placebo + IFN beta-1a + Methylprednisolone

    Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.

    Drug: Placebo · Biological: IFN beta-1a · Drug: Methylprednisolone

Interventions

  • Dietary supplementD-aspartate

    D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.

  • DrugPlacebo

    Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.

  • BiologicalIFN beta-1a

    IFN beta-1a was administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.

  • Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8

    EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).

    Time frame: Baseline, Week 8

Secondary outcomes

  1. Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24

    EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis. It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).

    Time frame: Baseline, Week 12 and 24

  2. 25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

    The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The participants is directed to one end of a clearly marked 25-foot (7.62 m) course and is instructed to walk 25 feet (7.62 meter) as quickly as possible, but safely. The task is immediately administered again by having the participant walk back the same distance. Participants may use assistive devices when doing this task. The test scores were the time in seconds it took to walk the 25 feet. The data for the 25-FWT is reported for the 2 completed trials. Participant wise data was reported for this outcome.

    Time frame: At Week 8, 12 and 24

  3. 9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

    The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The data for the 29HPT is reported for the 2 completed trials. Participant wise data was reported for this outcome.

    Time frame: Week 8, 12 and 24

  4. Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

    Symbol digit modalities test is to evaluate neurocognitive functions. This measure involves a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. The participants is required to scan the key and write down the number corresponding to each symbol as fast as possible. The number of correct substitution within 90 seconds is recorded. In the written version of the test the participants fills in the numbers that correspond to the symbols. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates better performance. Participant wise data was reported for this outcome.

    Time frame: At Week 8, 12 and 24

  5. Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

    Visual acuity is measured under low contrast conditions (10% contrast relative to the chart background) at object testing distances of 10 feets and is reported as the number of letters read correctly (ranging from 0 to 10 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. Participant wise data was reported for this outcome.

    Time frame: Week 8, 12 and 24

  6. Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24

    MFIS is a structured, self-report questionnaire consisting of 21 items assessing the effects of fatigue. All 21 items are scaled 0 to 4, with higher scores indicating a greater impact of fatigue on participant's activities. The Total MFIS score ranges from 0 to 84. A score of 0 indicates fatigue has no impact on activities and the high-end score indicates fatigue has extreme impact on activities. Participant wise data was reported for this outcome.

    Time frame: Week 8, 12 and 24

  7. Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24

    Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue. Participant wise data was reported for this outcome.

    Time frame: Week 8, 12 and 24

  8. Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)

    TMS is an electrophysiological technique that was used to measure neurologic changes associated with recovery from stroke via alterations in the excitability of the motor system. Motor threshold measures reflect global excitability of the corticospinal pathway, including large pyramidal cells, excitatory/inhibitory interneurons, and spinal motor neurons. Long term potentiation can be measured non invasively and painlessly, in awake humans through transcranial magnetic stimulation (TMS). TMS uses high intensity, brief duration, magnetic fields that, when applied on the scalp, can activate neurons within a small focal region of the cerebral cortex, through electromagnetic induction. Motor Evoked Potentials (MEP) amplitudes elicited by single TMS pulses of increasing intensity (110, 120 and 130% of the Resting Motor Threshold \[RMT\]) will be measured to calculate recruitment curves of the motor cortex. Participant wise data was reported for this outcome.

    Time frame: Baseline (0 minute) and Post-Baseline (15 minutes) at Week 8

  9. Number of Treated Participants With Immune-metabolic Response of Lymphocytes

    Treated participants with immune-metabolic response (glycolysis, mitochondrial respiration, fatty acids oxidation and circulating adipocytokines) of lymphocytes were to be reported.

    Time frame: Baseline, Week 8 and 12

07

Results

Posted Feb 10, 2020
Limitations and caveats
Study was prematurely terminated, due to slow recruitment rate.

Participant flow

Participant flow — Overall Study
MilestoneD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Started52
Completed41
Not completed11
Withdrew: Adverse event11

Outcome measures

PrimaryNumber of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8

EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).

Time frame:
Baseline, Week 8
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 8
ParticipantsD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 810
SecondaryNumber of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24

EDSS is an ordinal scale in half-point increments that qualifies disability in participants with Multiple Sclerosis. It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS).

Time frame:
Baseline, Week 12 and 24
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Multiple Sclerosis Related Disability Measured by Expanded Disability Status Scale (EDSS) at Week 12 and 24
ParticipantsD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Week 1210
Week 2410
Secondary25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The participants is directed to one end of a clearly marked 25-foot (7.62 m) course and is instructed to walk 25 feet (7.62 meter) as quickly as possible, but safely. The task is immediately administered again by having the participant walk back the same distance. Participants may use assistive devices when doing this task. The test scores were the time in seconds it took to walk the 25 feet. The data for the 25-FWT is reported for the 2 completed trials. Participant wise data was reported for this outcome.

Time frame:
At Week 8, 12 and 24
Reported as:
Number · Seconds
25-foot Timed Walk (25-FWT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
SecondsD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Participant 1: Trial 1: Week 813.1—
Participant 1: Trial 2: Week 812.4—
Participant 2: Trial 1: Week 812.7—
Participant 2: Trial 2: Week 812.6—
Participant 3: Trial 1: Week 817.4—
Participant 3: Trial 2: Week 816.3—
Participant 4: Trial 1: Week 811.3—
Participant 4: Trial 2: Week 810.9—
Participant 5: Trial 1: Week 85.6—
Participant 5: Trial 2: Week 85.7—
Participant 6: Trial 1: Week 8—16.1
Participant 6: Trial 2: Week 8—14.3
Participant 7: Trial 1: Week 8—9.3
Participant 7: Trial 2: Week 8—8.9
Participant 1: Trial 1: Week 1213.1—
Participant 1: Trial 2: Week 1213.8—
Participant 3: Trial 1: Week 1217.1—
Participant 3: Trial 2: Week 1215.8—
Participant 4: Trial 1: Week 1210.9—
Participant 4: Trial 2: Week 1210.2—
Participant 5: Trial 1: Week 125.7—
Participant 5: Trial 2: Week 125.6—
Participant 6: Trial 1: Week 12—12.7
Participant 6: Trial 2: Week 12—12.3
Participant 7: Trial 1: Week 12—12.4
Participant 7: Trial 2: Week 12—11.8
Participant 1: Trial 1: Week 2411.8—
Participant 1: Trial 2: Week 2411.5—
Participant 3: Trial 1: Week 248.6—
Participant 3: Trial 2: Week 249.3—
Participant 4: Trial 1: Week 2411.4—
Participant 4: Trial 2: Week 2411.5—
Participant 5: Trial 1: Week 245.0—
Participant 5: Trial 2: Week 245.3—
Participant 7: Trial 1: Week 24—10.1
Participant 7: Trial 2: Week 24—9.8
Secondary9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The data for the 29HPT is reported for the 2 completed trials. Participant wise data was reported for this outcome.

Time frame:
Week 8, 12 and 24
Reported as:
Number · Seconds
9 Hole Peg Test (9HPT) to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
SecondsD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Participant 1: Trial 1: Week 8: Dominant hand22.1—
Participant 1: Trial 2: Week 8: Dominant hand21.1—
Participant 2: Trial 1: Week 8: Dominant hand18.7—
Participant 2: Trial 2: Week 8: Dominant hand17.6—
Participant 3: Trial 1: Week 8: Dominant hand19.7—
Participant 3: Trial 2: Week 8: Dominant hand16.3—
Participant 4: Trial 1: Week 8: Dominant hand17.8—
Participant 4: Trial 2: Week 8: Dominant hand17.2—
Participant 5: Trial 1: Week 8: Dominant hand22.6—
Participant 5: Trial 2: Week 8: Dominant hand25.5—
Participant 6: Trial 1: Week 8: Dominant hand—17.5
Participant 6: Trial 2: Week 8: Dominant hand—17.2
Participant 7: Trial 1: Week 8: Dominant hand—31.9
Participant 7: Trial 2: Week 8: Dominant hand—9.5
Participant 1: Trial 1: Week 12: Dominant hand24.2—
Participant 1: Trial 2: Week 12: Dominant hand22.0—
Participant 3: Trial 1: Week 12: Dominant hand17.6—
Participant 3: Trial 2: Week 12: Dominant hand17.8—
Participant 4: Trial 1: Week 12: Dominant hand16.8—
Participant 4: Trial 2: Week 12: Dominant hand16.1—
Participant 5: Trial 1: Week 12: Dominant hand25.3—
Participant 5: Trial 2: Week 12: Dominant hand23.2—
Participant 6: Trial 1: Week 12: Dominant hand—21.1
Participant 6: Trial 2: Week 12: Dominant hand—17.9
Participant 7: Trial 1: Week 12: Dominant hand—31.6
Participant 7: Trial 2: Week 12: Dominant hand—29.8
Participant 1: Trial 1: Week 24: Dominant hand22.0—
Participant 1: Trial 2: Week 24: Dominant hand21.5—
Participant 3: Trial 1: Week 24: Dominant hand18.8—
Participant 3: Trial 2: Week 24: Dominant hand18.1—
Participant 4: Trial 1: Week 24: Dominant hand17.2—
Participant 4: Trial 2: Week 24: Dominant hand16.7—
Participant 5: Trial 1: Week 24: Dominant hand27.4—
Participant 5: Trial 2: Week 24: Dominant hand24.6—
Participant 7: Trial 1: Week 24: Dominant hand—32.6
Participant 7: Trial 2: Week 24: Dominant hand—30.8
Participant 1: Trial 1: Week 8: Non-Dominant hand25.2—
Participant 1: Trial 2: Week 8: Non-Dominant hand25.3—
Participant 2: Trial 1: Week 8: Non-Dominant hand18.9—
Participant 2: Trial 2: Week 8: Non-Dominant hand17.3—
Participant 3: Trial 1: Week 8: Non-Dominant hand21.4—
Participant 3: Trial 2: Week 8: Non-Dominant hand20.7—
Participant 4: Trial 1: Week 8: Non-Dominant hand18.9—
Participant 4: Trial 2: Week 8: Non-Dominant hand19.7—
Participant 5: Trial 1: Week 8: Non-Dominant hand22.0—
Participant 5: Trial 2: Week 8: Non-Dominant hand20.8—
Participant 6: Trial 1: Week 8: Non-Dominant hand—19.5
Participant 6: Trial 2: Week 8: Non-Dominant hand—19.9
Participant 7: Trial 1: Week 8: Non-Dominant hand—22.0
Participant 7: Trial 2: Week 8: Non-Dominant hand—21.1
Participant 1: Trial 1: Week 12: Non-Dominant hand22.8—
Participant 1: Trial 2: Week 12: Non-Dominant hand19.8—
Participant 3: Trial 1: Week 12: Non-Dominant hand20.8—
Participant 3: Trial 2: Week 12: Non-Dominant hand22.5—
Participant 4: Trial 1: Week 12: Non-Dominant hand17.3—
Participant 4: Trial 2: Week 12: Non-Dominant hand17.5—
Participant 5: Trial 1: Week 12: Non-Dominant hand22.8—
Participant 5: Trial 2: Week 12: Non-Dominant hand23.7—
Participant 6: Trial 1: Week 12: Non-Dominant hand—20.6
Participant 6: Trial 2: Week 12: Non-Dominant hand—20.4
Participant 7: Trial 1: Week 12: Non-Dominant hand—24.5
Participant 7: Trial 2: Week 12: Non-Dominant hand—25.7
Participant 1: Trial 1: Week 24: Non-Dominant hand22.4—
Participant 1: Trial 2: Week 24: Non-Dominant hand20.5—
Participant 3: Trial 1: Week 24: Non-Dominant hand20.1—
Participant 3: Trial 2: Week 24: Non-Dominant hand18.4—
Participant 4: Trial 1: Week 24: Non-Dominant hand18.1—
Participant 4: Trial 2: Week 24: Non-Dominant hand18.3—
Participant 5: Trial 1: Week 24: Non-Dominant hand25.8—
Participant 5: Trial 2: Week 24: Non-Dominant hand22.7—
Participant 7: Trial 1: Week 24: Non-Dominant hand—24.1
Participant 7: Trial 2: Week 24: Non-Dominant hand—23.6
SecondarySymbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

Symbol digit modalities test is to evaluate neurocognitive functions. This measure involves a coding key consisting of 9 abstract symbols, each paired with a number ranging from 1 to 9. The participants is required to scan the key and write down the number corresponding to each symbol as fast as possible. The number of correct substitution within 90 seconds is recorded. In the written version of the test the participants fills in the numbers that correspond to the symbols. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates better performance. Participant wise data was reported for this outcome.

Time frame:
At Week 8, 12 and 24
Reported as:
Number · units on a scale
Symbol Digit Modalities Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
units on a scaleD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Participant 1: Week 838—
Participant 2: Week 843—
Participant 3: Week 848—
Participant 4: Week 866—
Participant 5: Week 846—
Participant 6: Week 8—56
Participant 7: Week 8—43
Participant 1: Week 1248—
Participant 3: Week 1244—
Participant 4: Week 1268—
Participant 5: Week 1244—
Participant 6: Week 12—46
Participant 7: Week 12—43
Participant 1: Week 2450—
Participant 3: Week 2451—
Participant 4: Week 2470—
Participant 5: Week 2439—
Participant 7: Week 24—55
SecondaryLow Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment

Visual acuity is measured under low contrast conditions (10% contrast relative to the chart background) at object testing distances of 10 feets and is reported as the number of letters read correctly (ranging from 0 to 10 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. Participant wise data was reported for this outcome.

Time frame:
Week 8, 12 and 24
Reported as:
Number · Letters read correctly
Low Contrast Letter Visual Acuity Test to Measure Multiple Sclerosis Related Disability and Cognitive Impairment
Letters read correctlyD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Participant 1: Week 8: Left eye4—
Participant 2: Week 8: Left eye8—
Participant 3: Week 8: Left eye8—
Participant 4: Week 8: Left eye8—
Participant 6: Week 8: Left eye—8
Participant 7: Week 8: Left eye—8
Participant 1: Week 12: Left eye2—
Participant 3: Week 12: Left eye10—
Participant 4: Week 12: Left eye8—
Participant 6: Week 12: Left eye—8
Participant 7: Week 12: Left eye—9
Participant 1: Week 24: Left eye3—
Participant 3: Week 24: Left eye10—
Participant 4: Week 24: Left eye10—
Participant 7: Week 24: Left eye—8
Participant 1: Week 8: Right eye4—
Participant 2: Week 8: Right eye8—
Participant 3: Week 8: Right eye2—
Participant 4: Week 8: Right eye7—
Participant 6: Week 8: Right eye—8
Participant 7: Week 8: Right eye—8
Participant 1: Week 12: Right eye8—
Participant 3: Week 12: Right eye10—
Participant 4: Week 12: Right eye7—
Participant 6: Week 12: Right eye—8
Participant 7: Week 12: Right eye—9
Participant 1: Week 24: Right eye8—
Participant 3: Week 24: Right eye10—
Participant 4: Week 24: Right eye10—
Participant 7: Week 24: Right eye—8
SecondaryModified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24

MFIS is a structured, self-report questionnaire consisting of 21 items assessing the effects of fatigue. All 21 items are scaled 0 to 4, with higher scores indicating a greater impact of fatigue on participant's activities. The Total MFIS score ranges from 0 to 84. A score of 0 indicates fatigue has no impact on activities and the high-end score indicates fatigue has extreme impact on activities. Participant wise data was reported for this outcome.

Time frame:
Week 8, 12 and 24
Reported as:
Number · units on a scale
Modified Fatigue Impact Scale (MFIS) Score to Measure Fatigue at Week 8, 12 and 24
units on a scaleD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Participant 1: Week 88—
Participant 2: Week 827—
Participant 3: Week 815—
Participant 4: Week 82—
Participant 5: Week 818—
Participant 6: Week 8—27
Participant 7: Week 8—29
Participant 1: Week 126—
Participant 3: Week 1212—
Participant 4: Week 1212—
Participant 5: Week 1215—
Participant 6: Week 12—27
Participant 7: Week 12—30
Participant 1: Week 2410—
Participant 3: Week 2448—
Participant 4: Week 2412—
Participant 5: Week 2415—
Participant 7: Week 24—43
SecondaryFatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24

Fatigue Severity Scale (FSS) is a method of evaluating fatigue in multiple sclerosis and is designed to differentiate fatigue from clinical depression, since both share some of the same symptoms. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue. Participant wise data was reported for this outcome.

Time frame:
Week 8, 12 and 24
Reported as:
Number · units on a scale
Fatigue Severity Scale (FSS) Score to Measure Fatigue by at Week 8, 12 and 24
units on a scaleD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Participant 1: Week 81.2—
Participant 2: Week 82.6—
Participant 3: Week 81.7—
Participant 4: Week 81.1—
Participant 5: Week 81—
Participant 6: Week 8—4.3
Participant 7: Week 8—2.2
Participant 1: Week 121.3—
Participant 3: Week 122.6—
Participant 4: Week 122—
Participant 5: Week 121—
Participant 6: Week 12—4.1
Participant 7: Week 12—4.1
Participant 1: Week 241.3—
Participant 3: Week 242.8—
Participant 4: Week 242—
Participant 5: Week 241.1—
Participant 7: Week 24—3.3
SecondaryLong Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)

TMS is an electrophysiological technique that was used to measure neurologic changes associated with recovery from stroke via alterations in the excitability of the motor system. Motor threshold measures reflect global excitability of the corticospinal pathway, including large pyramidal cells, excitatory/inhibitory interneurons, and spinal motor neurons. Long term potentiation can be measured non invasively and painlessly, in awake humans through transcranial magnetic stimulation (TMS). TMS uses high intensity, brief duration, magnetic fields that, when applied on the scalp, can activate neurons within a small focal region of the cerebral cortex, through electromagnetic induction. Motor Evoked Potentials (MEP) amplitudes elicited by single TMS pulses of increasing intensity (110, 120 and 130% of the Resting Motor Threshold \[RMT\]) will be measured to calculate recruitment curves of the motor cortex. Participant wise data was reported for this outcome.

Time frame:
Baseline (0 minute) and Post-Baseline (15 minutes) at Week 8
Reported as:
Number · millivolts
Long Term Potentiation Measured by Transcranial Magnetic Stimulation (TMS)
millivoltsD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Participants 1: Week 8 (Baseline): 110% RMT30—
Participants 1: Week 8 (Baseline): 120% RMT105—
Participants 1: Week 8 (Baseline): 130% RMT142—
Participants 1: Week 8 (Post-baseline): 110% RMT39—
Participants 1: Week 8 (Post-baseline): 120% RMT128—
Participants 1: Week 8 (Post-baseline): 130% RMT154—
Participants 3: Week 8 (Baseline): 110% RMT23—
Participants 3: Week 8 (Baseline): 120% RMT95—
Participants 3: Week 8 (Baseline): 130% RMT115—
Participants 3: Week 8 (Post-baseline): 110% RMT31—
Participants 3: Week 8 (Post-baseline): 120% RMT103—
Participants 3: Week 8 (Post-baseline): 130% RMT118—
Participants 6: Week 8 (Baseline): 110% RMT—28
Participants 6: Week 8 (Baseline): 120% RMT—83
Participants 6: Week 8 (Baseline): 130% RMT—118
Participants 6: Week 8 (Post-baseline): 110% RMT—26
Participants 6: Week 8 (Post-baseline): 120% RMT—91
Participants 6: Week 8 (Post-baseline): 130% RMT—125
Participants 7: Week 8 (Baseline): 110% RMT—33
Participants 7: Week 8 (Baseline): 120% RMT—140
Participants 7: Week 8 (Baseline): 130% RMT—149
Participants 7: Week 8 (Post-baseline): 110% RMT—30
Participants 7: Week 8 (Post-baseline): 120% RMT—135
Participants 7: Week 8 (Post-baseline): 130% RMT—138
SecondaryNumber of Treated Participants With Immune-metabolic Response of Lymphocytes

Treated participants with immune-metabolic response (glycolysis, mitochondrial respiration, fatty acids oxidation and circulating adipocytokines) of lymphocytes were to be reported.

Time frame:
Baseline, Week 8 and 12

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to 292 days; Participants were assessed for adverse events for the entire study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
D-aspartate + IFN Beta-1a + Methylprednisolone0/5 (0%)0/5 (0%)3/5 (60%)
Placebo + IFN Beta-1a + Methylprednisolone0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Most frequent other events
EventD-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + Methylprednisolone
Flu-like symptomsInfections and infestations1/51/2
Periorbital painEye disorders0/51/2
HypersexualityReproductive system and breast disorders1/50/2
Weight gainGeneral disorders1/50/2
Pain in the left thighGeneral disorders1/50/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)D-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + MethylprednisoloneTotal
<=18 years000
Between 18 and 65 years527
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)D-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + MethylprednisoloneTotal
Female202
Male325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)D-aspartate + IFN Beta-1a + MethylprednisolonePlacebo + IFN Beta-1a + MethylprednisoloneTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White527
More than one race000
Unknown or Not Reported000
08

Study locations

17 sites
  • Ospedale Binaghi, Università di Cagliari,ASL 8
    Cagliari, Italy
  • Ospedale Clinicizzato SS. Annunziata
    Chieti, Italy
  • Azienda Socio Sanitaria Territoriale della Valle Olona (presidio di Gallarate)
    Gallarate, Italy
  • Azienda Ospedaliero Universitaria San Martino
    Genova, Italy
  • Ospedale P.A.Micone
    Genova, Italy
  • Ospedale San Raffaele
    Milano, Italy
  • A.O.U. Federico II
    Napoli, Italy
  • Azienda Ospedaliera di Rilievo Nazionale A. CardarelliAzienda Ospedaliera di Rilievo Nazionale A. Cardarelli
    Napoli, Italy
  • Seconda Università degli Studi di Napoli
    Napoli, Italy
  • Azienda Ospedaliera di Padova
    Padova, Italy
  • I.R.C.C.S. Neuromed-Istituto Neurologico Mediterraneo
    Pozzilli, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Roma, Italy
  • Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza
    Roma, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, Italy
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    Rome, Italy
  • Ospedale S. Paolo
    Savona, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti
    Torrette Di Ancona, Italy
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Jan 2019, 9 months.

Results were first posted in Feb 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2017
First posted
Dec 29, 2017
StartActual
Mar 26, 2018
Primary completionActual
Jan 11, 2019
CompletionActual
Jan 11, 2019
Results first posted
Feb 10, 2020
Last update
Feb 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03387046
Responsible party
Sponsor
First posted
Dec 29, 2017
Start date
Mar 26, 2018
Primary completion
Jan 11, 2019
Completion
Jan 11, 2019
Results posted
Feb 10, 2020
Last update
Feb 10, 2020

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion